Literature DB >> 27436923

Variability in orthopedic surgeon treatment preferences for nondisplaced scaphoid fractures: A cross-sectional survey.

Megan Carroll Paulus1, Jake Braunstein2, Daniel Merenstein3, Steven Neufeld4, Michael Narvaez2, Robert Friedland5, Katherine Bruce5, Ashley Pfaff2.   

Abstract

PURPOSE: The absence of a best practice treatment standard contributes to clinical variation in medicine. Often in the absence of evidence, a standard of care is developed and treatment protocols are implemented. The purpose of this study was to examine whether the standard of care for the treatment of nondisplaced scaphoid fractures is uniform among orthopedic surgeons.
METHODS: A survey of orthopedic surgeons actively practicing in the US or abroad was conducted to elicit preferred treatment strategies for nondisplaced scaphoid fractures. The surgeons were recruited at orthopedic conferences, clinical visits, and via email. The survey included demographic questions along with a short clinical vignette. The option for fracture management included surgical versus nonsurgical treatment. For those who chose nonsurgical treatment, type/duration of immobilization was recorded. Cost analysis was performed to estimate direct and indirect costs of various treatment options.
RESULTS: A total of 494 orthopedic surgeons completed the survey. The preference for surgical treatment was preferred in 13% of respondents. Hand/upper extremity specialists were significantly more likely to operate compared with generalists (p = 0.0002). Surgeons younger than forty-five were nearly twice as likely to choose surgery (p = 0.01). There was no clear consensus on duration of immobilization as 30% of surgeons chose 6 weeks, 33% selected 8 weeks, and 27% opted for 12 weeks. Total cost of surgery was 49% greater than that of nonoperative treatment. With each additional week of immobilization for nonoperative treatment, the total costs of surgical treatment near that of nonoperative treatment.
CONCLUSION: There exist clear trends in how specific demographic groups choose to treat the nondisplaced scaphoid fracture. Whether these trends are the result of generational gaps or additional subspecialty training remains difficult to determine, but there is need to pursue a more consistent approach that benefits the patients and the health care system as a whole.

Entities:  

Keywords:  Cost analysis; Nondisplaced; Scaphoid fracture; Treatment

Year:  2016        PMID: 27436923      PMCID: PMC4939409          DOI: 10.1016/j.jor.2016.06.020

Source DB:  PubMed          Journal:  J Orthop        ISSN: 0972-978X


  7 in total

1.  A cost/utility analysis of open reduction and internal fixation versus cast immobilization for acute nondisplaced mid-waist scaphoid fractures.

Authors:  Erika N Davis; Kevin C Chung; Sandra V Kotsis; Frank H Lau; Sandeep Vijan
Journal:  Plast Reconstr Surg       Date:  2006-04       Impact factor: 4.730

2.  Comparison of direct and indirect costs of internal fixation and cast treatment in acute scaphoid fractures: a randomized trial involving 52 patients.

Authors:  Bertil Vinnars; Fredrik Af Ekenstam; Bengt Gerdin
Journal:  Acta Orthop       Date:  2007-10       Impact factor: 3.717

Review 3.  Surgical versus nonsurgical treatment of acute minimally displaced and undisplaced scaphoid waist fractures: pairwise and network meta-analyses of randomized controlled trials.

Authors:  Talal Ibrahim; Assad Qureshi; Alex J Sutton; Joseph J Dias
Journal:  J Hand Surg Am       Date:  2011-11       Impact factor: 2.230

Review 4.  Treatment of acute scaphoid fractures: systematic review and meta-analysis.

Authors:  Zhong-Gang Yin; Jian-Bing Zhang; Shi-Lian Kan; Pei Wang
Journal:  Clin Orthop Relat Res       Date:  2007-07       Impact factor: 4.176

5.  Acute non-displaced fractures of the scaphoid: earlier return to activities after operative treatment. A controlled multicenter cohort study.

Authors:  Michael Schädel-Höpfner; Marta Marent-Huber; Emre Gazyakan; Karin Tanzer; Klaus D Werber; Hartmut R Siebert
Journal:  Arch Orthop Trauma Surg       Date:  2009-11-17       Impact factor: 3.067

6.  Non-operative treatment of non-displaced scaphoid fractures may be preferred.

Authors:  Steven J Rhemrev; Roderick H van Leerdam; Daan Ootes; Frank J P Beeres; Sven A G Meylaerts
Journal:  Injury       Date:  2009-03-25       Impact factor: 2.586

Review 7.  Evidence-based management of acute nondisplaced scaphoid waist fractures.

Authors:  Ashwin N Ram; Kevin C Chung
Journal:  J Hand Surg Am       Date:  2009-04       Impact factor: 2.230

  7 in total
  5 in total

1.  How Do Spinal Surgeons Perceive The Impact of Factors Used in Post-Surgical Complication Risk Scores?

Authors:  Enea Parimbelli; Wilk Szymon; Dympna O'Sullivan; Stephen Kingwell; Wojtek Michalowski; Martin Michalowski
Journal:  AMIA Annu Symp Proc       Date:  2020-03-04

2.  Do Patient Preferences Influence Surgeon Recommendations for Treatment?

Authors:  Lisanne J H Smits; Suzanne C Wilkens; David Ring; Thierry G Guitton; Neal C Chen
Journal:  Arch Bone Jt Surg       Date:  2019-03

Review 3.  A Systematic Review and Meta-analysis of Randomized Controlled Trials Comparing Surgical versus Conservative Treatments for Acute Undisplaced or Minimally-Displaced Scaphoid Fractures.

Authors:  Turki A Al-Ajmi; Khalid H Al-Faryan; Naif F Al-Kanaan; Abdulmalik A Al-Khodair; Thamer H Al-Faryan; Maher I Al-Oraini; Abdulelah F Bassas
Journal:  Clin Orthop Surg       Date:  2018-02-27

4.  Variation in the Reported Management of Canine Prolapsed Nictitans Gland and Feline Herpetic Keratitis.

Authors:  Constance N White; Gareth Jones; Sarah Baker; Rachel S Dean; Marnie L Brennan
Journal:  Vet Sci       Date:  2018-06-01

5.  Factors associated with surgeon recommendation for additional cast immobilization of a CT-verified nondisplaced scaphoid waist fracture.

Authors:  Anne Eva J Bulstra; Tom J Crijns; Stein J Janssen; Geert A Buijze; David Ring; Ruurd L Jaarsma; Gino M M J Kerkhoffs; Miryam C Obdeijn; Job N Doornberg
Journal:  Arch Orthop Trauma Surg       Date:  2021-07-24       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.